Vaprisol (conivaptan hydrochloride injection) Premixed in 5%Dextrose, a new formulation of Vaprisol developed by Astellas Pharma US, Inc., hasbeen approved for the treatment of both euvolemic and hypervolemic hyponatremiain hospitalized patients.


Continue Reading

The ampule formulation of Vaprisol, an argininevasopressin receptor antagonist, was originally cleared by the FDA for thetreatment of euvolemic hyponatremia in December 2005 and hypervolemichyponatremia in February 2007.


“This [new] ready-to-use product will be usefulfor hospitals and emergency rooms,” said Joseph Verbalis, MD, professor ofmedicine and physiology at Georgetown University in Washington,D.C.